Industry ownership intelligence

Medical Devices insider conviction

Executive and director activity assessed across 82 companies for breadth, transaction quality, clustering, freshness, and directional conviction.

Market dashboardHealthcare sectorCompany signalsFiling ledgerData API
47/100

Balanced insider tape

90/100 confidence
Level
Industry
Evidence window
Latest 90 days
Named insiders
654
Latest evidence
7 Aug 2026

Capital positioning read

Balanced insider tape

Acquisition and disposal evidence is mixed after low-information compensation and derivative activity is separated out.

Wait for clearer clustering

Evidence in favour

  • 132 distinct acquisition events survive duplicate and security-type controls.
  • Participation spans 654 named insiders rather than one filing source.
  • The latest qualifying evidence is fresh, dated 07 Aug 2026.

Decision risks

  • Qualifying disposal events outnumber acquisitions, although disposals receive a lower directional weight.
Conviction47Balanced insider tape
Confidence90Deep evidence
Controlled events543directional common-share events
Company breadth82represented companies
Acquisition value$28.6Mnormalized amount
Disposal value$274.7Mnormalized amount

Flow regime

Twelve-week filing pressure

Shows the cadence and balance of the full filing tape.

15825 May
30901 Jun
16008 Jun
15715 Jun
7922 Jun
11129 Jun
7006 Jul
4213 Jul
3120 Jul
8227 Jul
5303 Aug
010 Aug
AcquisitionsDisposalsScore 47 · Confidence 90

Relative positioning

Industry peer map

Current score with confidence.

Pharmaceutical RetailersConviction accumulation7216 confidence Medical DistributionAccumulation bias6774 confidence Drug Manufacturers - GeneralBalanced insider tape5694 confidence BiotechnologyBalanced insider tape5391 confidence Medical DevicesBalanced insider tape4790 confidence Diagnostics & ResearchDistribution bias3894 confidence Medical Care FacilitiesDistribution bias3793 confidence Health Information ServicesDistribution bias3692 confidence Medical Instruments & SuppliesDistribution bias3691 confidence Drug Manufacturers - Specialty & GenericDistribution bias3594 confidence Healthcare PlansDistribution bias3492 confidence

Directional balance

Controlled event mix

24.3%acquisition
Acquisition events
132
Disposal events
411
Net value
-$246.2M

Evidence quality

What the filings represent

Common equity1121
Equity compensation332
Options and derivatives235
Other securities10

Decision makers

Role participation

Director888
Other executive331
CEO and chair164
Finance leadership139
Other or unspecified122
Large holder54

Quality controls

Evidence usability

Normalized values
35%
Priced common share
34%
Named insiders
654
Controlled events
543

Auditable evidence

Latest Medical Devices filings

Showing 811 to 840 of 1698.

LUNGPulmonx Corp
FERRARI, RICHARDDirector
AcquisitionCommon equity
Not reportedContext evidence
LUNGPulmonx Corp
FLORIN, DANIEL PDirector
AcquisitionCommon equity
Not reportedContext evidence
LUNGPulmonx Corp
MEAD, DANA G JR.Director
AcquisitionCommon equity
Not reportedContext evidence
LUNGPulmonx Corp
MELENIKIOTOU, GEORGIADirector
AcquisitionCommon equity
Not reportedContext evidence
LUNGPulmonx Corp
SULLIVAN, TIFFANYDirector
AcquisitionCommon equity
Not reportedContext evidence
NPCENeuropace Inc
ANDRADE, LISADirector
AcquisitionOptions and derivatives
Not reportedContext evidence
NPCENeuropace Inc
ANDRADE, LISADirector
AcquisitionCommon equity
Not reportedContext evidence
NPCENeuropace Inc
FISCHER, FRANK MDirector
AcquisitionCommon equity
Not reportedContext evidence
NPCENeuropace Inc
FISCHER, FRANK MDirector
AcquisitionOptions and derivatives
Not reportedContext evidence
NPCENeuropace Inc
GEIGER, URIDirector
AcquisitionCommon equity
Not reportedContext evidence
NPCENeuropace Inc
GEIGER, URIDirector
AcquisitionOptions and derivatives
Not reportedContext evidence
NPCENeuropace Inc
HUENNEKENS, R SCOTTDirector
AcquisitionOptions and derivatives
Not reportedContext evidence
NPCENeuropace Inc
HUENNEKENS, R SCOTTDirector
AcquisitionCommon equity
Not reportedContext evidence
NPCENeuropace Inc
KUMAR, RAKHIDirector
AcquisitionCommon equity
Not reportedContext evidence
NPCENeuropace Inc
KUMAR, RAKHIDirector
AcquisitionOptions and derivatives
Not reportedContext evidence
NPCENeuropace Inc
RYAN, RENEEDirector
AcquisitionOptions and derivatives
Not reportedContext evidence
NPCENeuropace Inc
RYAN, RENEEDirector
AcquisitionCommon equity
Not reportedContext evidence
UFPTUFP Technologies Inc
BAILLY, R JEFFREYDirector, Executive Chairman
AcquisitionCommon equity
Not reportedContext evidence
GMEDGlobus Medical
DAVIDAR, DAVID DDirector
DisposalCommon equity
$2.0MDirectional evidence
GMEDGlobus Medical
DAVIDAR, DAVID DDirector
AcquisitionCommon equity
$656.8KDirectional evidence
BFLYButterfly Network Inc
CASHMAN, STEVEChief Business Officer
DisposalCommon equity
$520.1KDirectional evidence
STESTERIS plc
CARESTIO, DANIEL ADirector, President and CEO
DisposalCommon equity
$291.3KDirectional evidence
UFPTUFP Technologies Inc
BAILLY, R JEFFREYDirector, Executive Chairman
DisposalCommon equity
$167.9KDirectional evidence
SIBNSi-Bone Inc
DUNN, JEFFREY WDirector
DisposalCommon equity
$54.5KDirectional evidence
HAEHaemonetics Corporation
MILLER, LAURIE A.SVP, Human Resources
DisposalCommon equity
$22.3KDirectional evidence
MDTMedtronic PLC
BLOMQUIST, DENISE L.Chief Accounting Officer
DisposalCommon equity
$19.7KDirectional evidence
HAEHaemonetics Corporation
MAUNSELL, FARRIS MARYANNEVP, Chief Accounting Officer
DisposalCommon equity
$18.5KDirectional evidence
IRIXIRIDEX Corporation
DIZON, ROMEO RChief Financial Officer
AcquisitionCommon equity
$2.9KDirectional evidence
GMEDGlobus Medical
RHOADS, ANN DDirector
DisposalOptions and derivatives
Not reportedContext evidence
OMOutset Medical Inc
DREXLER, KARENDirector
AcquisitionCommon equity
Not reportedContext evidence

Group-level method

Breadth before headline value

Company breadth

A sector or industry score must be supported across companies. One very large filing cannot manufacture broad conviction.

Economic duplicates

Matching company, date, side, security class, share count, and value records are consolidated for the directional calculation.

Evidence hierarchy

Priced common-share activity determines direction. Compensation and derivative records are mapped separately so ownership mechanics remain visible.

Positioning use

The score identifies where insider alignment merits research or where disposal concentration needs review. Price, trend, valuation, and portfolio risk still decide positioning.

Independent market research for education. This classification is not investment advice, a recommendation, a forecast, or an execution instruction.

Evidence context